Assembly Biosciences' Herpes Drugs Show 98% Reduction in Viral Shedding in Phase I Studies
核心洞察
Assembly Biosciences reported striking Phase I results for two investigational herpes drugs, with ABI-1179 achieving a 98% reduction in HSV-2 (搜索) viral shedding and 91% reduction in genital lesions compared to placebo.
The weekly oral drug ABI-1179 exceeded the company's target of 80-85% shedding reduction, while monthly candidate ABI-5366 demonstrated 76% reduction in viral shedding and 88% decrease in confirmed genital lesions.
Both helicase-primase inhibitors showed superior efficacy potential compared to current nucleoside analog treatments, with Assembly planning Phase II trials for ABI-5366 by mid-2026.
Assembly Biosciences announced positive interim results from two Phase I studies of its investigational long-acting herpes simplex virus (搜索) (HSV) therapies, with both candidates demonstrating potent antiviral activity that exceeded company expectations. The California biotech's oral helicase-primase inhibitors showed striking reductions in viral shedding and genital lesions in patients with recurrent genital herpes (搜索).
Weekly Therapy Exceeds Efficacy Targets
In the ABI-1179 study, the 50-mg weekly oral dose achieved a 98% reduction in HSV-2 (搜索) shedding rate compared to placebo (p<0.01) over a 29-day evaluation period. This reduction significantly exceeded Assembly's target of 80-85% shedding reduction for the study. The drug also demonstrated a 91% reduction in virologically confirmed genital lesion rate compared to placebo (p<0.01) and showed a greater than 99% reduction in samples with high viral load, a potential surrogate indicator for HSV-2 transmission.
"As we saw with ABI-5366, weekly oral dosing of ABI-1179 outperformed our expectations for antiviral efficacy and improvement in clinical outcomes, and we are thrilled with these Phase 1b findings for both highly promising candidates," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Biosciences.
The study enrolled 50 participants across two dose cohorts, with 40 assigned to ABI-1179 and 10 to placebo. Both the 50-mg and 20-mg weekly doses showed statistically significant reductions in viral shedding rates of 98% and 92% respectively compared to placebo.
Monthly Dosing Shows Promise
The ABI-5366 monthly dose cohort demonstrated a 76% reduction in HSV-2 (搜索) shedding rate compared to placebo (p<0.01) over the 29-day evaluation period. An 88% reduction in virologically confirmed genital lesion rate (p=0.01) was observed, along with an 81% reduction in samples with high viral load (p<0.01) compared to placebo.
Notably, 89% of positive swabs in the monthly cohort were collected in the last two weeks of the evaluation period when drug levels were declining, suggesting the potential for optimized dosing regimens. The previously reported 350-mg weekly dose cohort of ABI-5366 showed even stronger results, with a 94% reduction in HSV-2 (搜索) shedding rate and 97% reduction in virologically confirmed genital lesion rate compared to placebo.
Superior Mechanism of Action
Both ABI-5366 and ABI-1179 work by targeting the viral helicase-primase (搜索) complex, an essential viral enzyme complex conserved across both HSV-1 and HSV-2 (搜索) that has no host equivalent. This mechanism represents a departure from current nucleoside analogs used for herpes treatment and has shown potential for superior efficacy in clinical studies.
Guggenheim Partners (搜索) analysts called the data "striking" in a Monday note to investors, adding that the readout "strongly reinforces the greater efficacy potential of [Assembly's] more potent, next-gen oral helicase-primase inhibitors." The analysts noted that ABI-1179 could unlock a "potential blockbuster novel weekly treatment opportunity" for the company.
Safety Profile and Development Timeline
Both drugs demonstrated favorable safety profiles across all evaluated doses. ABI-1179 was well-tolerated at oral doses up to 50 mg weekly, with treatment-emergent adverse events occurring in 80% of drug recipients compared to 88.9% of placebo recipients. The majority of adverse events were grade 1 or grade 2, with the most common being upper respiratory tract infections and headaches.
ABI-5366 showed similar tolerability, with 95.1% of drug recipients reporting treatment-emergent adverse events compared to 93.3% of placebo recipients. All adverse events were grade 1 or grade 2, and there have been no serious adverse events reported to date for either compound.
Assembly plans to advance ABI-5366 into Phase II trials by mid-2026, while continuing to evaluate the Phase II potential of ABI-1179. The company is progressing Phase 2 enabling activities for both candidates under its collaboration agreement with Gilead Sciences, which has the right to opt in to an exclusive license for further development and commercialization of the helicase-primase inhibitor program.
Addressing Unmet Medical Need
Genital herpes (搜索) affects over four million people in the United States, France, Germany, Italy, Spain and the United Kingdom who experience recurrent episodes. Most people with initial symptomatic genital HSV-2 (搜索) infection have three or more recurrences per year. Current nucleoside analog treatments are only partially effective in preventing recurrences and reducing viral transmission, and no new drugs have been approved in the United States or Europe to treat genital herpes for more than 25 years.
The helicase-primase inhibition mechanism represents a clinically validated approach that has demonstrated potential for superior efficacy compared to current standard of care in short-duration clinical studies. Assembly's results suggest these next-generation therapies could offer significant improvements in both dosing convenience and therapeutic outcomes for patients with recurrent genital herpes (搜索).